A new class of drugs for a novel biologic target

Pioneering science in the most advanced therapeutic program for this receptor

Certa has a pipleine of candidate drugs that target GPR68 each designed to address different fibrotic indications.

Figure: development pipeline as

Using genetic information to identify patients that will best respond to a specific treatment.

Precision medicine uses diagnostic tests to treat the right patients at the right time based on their genetic make-up and stage of disease.

Certa Therapeutics is seeking to combine our innovative therapeutics with biomarkers and genetic analysis to identify those patients most likely to benefit from treatment, providing potential for a precision therapy. 

We have demonstrated that many of the inflammatory and fibrotic molecular pathways dysregulated in animal models of chronic kidney disease are replicated in human disease in early phase trials.

In animals, FT011 (asengeprast) treatment broadly reverses inflammatory and fibrotic pathways back to a non-diseased state.


Scleroderma: a rare and potentially life-threatening autoimmune disorder characterised by inflammation and fibrosis of the skin and other organs.

Chronic Kidney Disease

Chronic kidney disease (CKD) encompasses all degrees of decreased kidney function, from mild or moderate disease to severe and end organ failure.

Focal Segmental Glomerulosclerosis

Focal segmental glomerulosclerosis is one of the many kidney conditions described under the umbrella of glomerulonephritis (inflammation of the kidney), which can lead to chronic kidney disease. FSGS is a condition that results in hardening or thickening of the glomeruli, which act as filters inside the nephrons of the kidney.

Diabetic Nephropathy

Diabetic nephropathy, or diabetic kidney disease (DKD) is a common complication of diabetes, where there is a decline in kidney function and reduced ability to filter out excess proteins from the blood.

Diabetic Retinopathy

Fibrosis is observed in multiple eye diseases, including diabetic retinopathy (DR) and age-related macular degeneration (AMD), where the deposition of scar tissue is irreversible, impacting vision and, in the case of DR, can ultimately lead to blindness.


All of the candidate drugs described on this site are investigational products which have not received marketing authorization or approval by any regulatory agency, including the US Food and Drug Administration, the European Medicines Agency, or the Australian Therapeutic Goods Agency. The investigational drug products are undergoing clinical studies to evaluate the safety and effectiveness in humans.